Phathom Pharmaceuticals (PHAT) Asset Utilization Ratio (2023 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Asset Utilization Ratio of 0.76 for Q2 2026, up 80.98% year-over-year from 0.42 in Q2 2025, and up 4.4% quarter-over-quarter from 0.73 in Q1 2026.
Phathom Pharmaceuticals (PHAT) Asset Utilization Ratio (2023 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Asset Utilization Ratio for 4 consecutive years, with 0.76 the latest figure, recorded in Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 80.98% year-over-year to 0.76; the TTM figure through Jun 2026 stood at 0.76 (up 80.98% YoY), while the FY2025 annual figure was 0.55, up 293.84% from the prior year.
- Asset Utilization Ratio climbed to 0.76 in Q2 2026 per PHAT's latest filing, from 0.73 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.76 in Q2 2026 and bottomed at 0.0 in Q4 2023.
- Historically, Asset Utilization Ratio has averaged 0.34 across 4 years, with a median of 0.24 in 2025.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio soared 6789.17% — and 2026, when it surged 80.98%.
- Phathom Pharmaceuticals' Asset Utilization Ratio stood at 0.0 in 2023, then jumped by 6789.17% to 0.14 in 2024, then surged by 385.68% to 0.7 in 2025, then gained by 8.12% to 0.76 in 2026.
- Business Quant data shows PHAT's Asset Utilization Ratio at 0.76 in Q2 2026, 0.73 in Q1 2026, and 0.7 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 0.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.76 |
| Mar 31, 2026 | 0.73 |
| Dec 31, 2025 | 0.70 |
| Sep 30, 2025 | 0.60 |
| Jun 30, 2025 | 0.42 |
| Mar 31, 2025 | 0.24 |
| Dec 31, 2024 | 0.14 |
| Sep 30, 2024 | 0.07 |
| Jun 30, 2024 | 0.03 |
| Mar 31, 2024 | 0.01 |
| Dec 31, 2023 | 0.00 |